![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/CONCORDBIO.png)
Share the post "Concord Biotech ‘s Q3 2024-25 Latest News: Profit Falls by 2.13% Year-on-Year"
Highlights
🔹 The presented financial data is Consolidated to provide a comprehensive overview of the company performance. 🔹 Sales over the Year and quarter: The company experienced a substantial growth of 1.42 % in the past year, decrease in net sales/revenue by -21.27 %. 🔹 Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 79.91 %. Marginal increase in other income during this quarter, up by 46.91%. 🔹 Profit over the Year and quarter: Challenges in sustaining profitability for Concord Biotech Limited. Profit dropped by -2.13 % Year to Year, Concord Biotech Limited’s profitability dropped by -20.7 % Quarter to Quarter. 🔹 EPS over the Year and quarter: EPS declined by -2.02 % Year to Year. EPS decreased by -20.66 % in previous quarter. Analysis needed for shareholder value.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 240.797 Cr | Rs. 310.181 Cr | Rs. 244.22 Cr | -21.27 % | + 1.42 % |
| Expenses | Rs. 134.86 Cr | Rs. 176.46 Cr | Rs. 146.27 Cr | -17.11 % | + 8.46 % |
| Operating Profit | Rs. 105.94 Cr | Rs. 133.72 Cr | Rs. 97.95 Cr | -26.75 % | -7.54 % |
| OPM % | 44 % | 43.11 % | 40.11 % | -3 % | -3.89 % |
| Other Income | Rs. 8.187 Cr | Rs. 10.026 Cr | Rs. 14.729 Cr | + 46.91 % | + 79.91 % |
| Interest | Rs. 0.5 Cr | Rs. 0.1 Cr | Rs. 0.1 Cr | + 0 % | -80 % |
| Depreciation | Rs. 13.54 Cr | Rs. 13.31 Cr | Rs. 13.26 Cr | -0.38 % | -2.07 % |
| Profit before tax | Rs. 100.09 Cr | Rs. 130.34 Cr | Rs. 99.32 Cr | -23.8 % | -0.77 % |
| Tax % | 25.51 % | 25.95 % | 25.4 % | -0.55 % | -0.11 % |
| Net Profit | Rs. 77.57 Cr | Rs. 95.74 Cr | Rs. 75.92 Cr | -20.7 % | -2.13 % |
| EPS in Rs | Rs. 7.41 | Rs. 9.15 | Rs. 7.26 | -20.66 % | -2.02 % |
Today, we’re looking at Concord Biotech Limited’s financial performance for the Q3(Dec 2024-25).Starting with the top line, the company reported a robust year-over-year sales growth of 1.42 %. However, it did see a marginal slip of -21.27 % from the previous quarter. Expenses decreased slightly by -17.11 % quarter-on-quarter, aligning with the annual rise of 8.46 %. Operating profit, while down -7.54 % compared to last year, faced a quarter-on-quarter dip of -26.75 %, signaling a short-term contraction in margins.
The Operating Profit Margin (OPM) % contradicts this narrative, showing weakness on an annual basis with a decrease of -3.89 %, but a shrinkage of -3 % sequentially. Other income rose by 46.91 % compared to the last quarter, despite an annual growth of 79.91 %. Interest expenses surged remarkably by 0 % from the previous quarter, yet the year-over-year decrease remains at a moderate -80 %. Depreciation costs fell by -0.38 % quarter-on-quarter, yet on an annual scale, they experienced a reduction of -2.07 %. Profit before tax declined annually by -0.77 % but saw a reduction from the preceding quarter by -23.8 %.
Tax expenses as a percentage of profits decreased slightly by -0.11 % compared to last year, with a more notable quarter-on-quarter decrease of -0.55 %. Net profit fell by -2.13 % year-on-year but witnessed a -20.7 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual downturn of -2.02 % but a quarterly fall of -20.66 %. In summary, Concord Biotech Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 240.797 Cr | Rs. 310.181 Cr | Rs. 244.22 Cr | -21.27 % | + 1.42 % |
| Expenses | Rs. 134.86 Cr | Rs. 176.46 Cr | Rs. 146.27 Cr | -17.11 % | + 8.46 % |
| Operating Profit | Rs. 105.94 Cr | Rs. 133.72 Cr | Rs. 97.95 Cr | -26.75 % | -7.54 % |
| Net Profit | Rs. 77.57 Cr | Rs. 95.74 Cr | Rs. 75.92 Cr | -20.7 % | -2.13 % |
| EPS in Rs | Rs. 7.41 | Rs. 9.15 | Rs. 7.26 | -20.66 % | -2.02 % |
In reviewing Concord Biotech Limited’s 2024-25(Q3) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 1.42 % year-on-year growth, although there was a slight dip of -21.27 % from the previous quarter. Expenses rose by 8.46 % compared to the previous year, with a decrease of -17.11 % quarter-on-quarter. Operating Profit dropped by -7.54 % annually, and saw a -26.75 % decrease from the last quarter.
Net Profit showed yearly decrease of -2.13 %, and experienced a -20.7 % decrease from the previous quarter. Earnings Per Share (EPS) fell by -2.02 % annually, however dipped by -20.66 % compared to the last quarter. In essence, while Concord Biotech Limited exhibits strong annual growth indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.
![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/WSI.png)
![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/VAIBHAVGBL.png)